$NAMS

RBC Capital reduced its price target for NewAmsterdam Pharma (NAMS) to $42 from $50, citing concerns over the Phase III PREVAIL trial's interim analysis. The stock is down 34% year-to-date, trading near its 52-week low. RBC estimates a 35-38% success probability for the interim analysis but sees a high chance of success by the end of 2027. The firm notes negative investor sentiment but potential favorable risk/reward at current levels.

RBC Capital maintained an Outperform rating on NewAmsterdam Pharma Co with a $42 price target, implying 81% upside from the Oct 2 close. The analyst cites strong trial potential for obicetrapib and favorable market positioning.

Kastelein Johannes Jacob Pieter (Chief Scientific Officer) sold 50,246 indirectly-held shares of NewAmsterdam Pharma Co N.V. (NAMS) at $25.03 ($1.26M total) on 2026-09-30 under a Rule 10b5-1 trading plan.

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeabl

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

NewAmsterdam Pharma (NAMS) and Menarini Group received European Commission approval for Ubeslo and Evlarco, treatments for high LDL-C. Data shows up to 50% LDL-C reduction. NAMS may receive royalties and milestone payments. NAMS stock is up 1.53% at $22.92.

NewAmsterdam Pharma (NAMS) shares rose 4% after CEO Michael H. Davidson bought 10,000 shares at $22.65 each, totaling $226.5K. Davidson now holds 792,923 shares directly and 285,715 indirectly. The purchase was disclosed in an SEC Form 4 filing. Investing.com's AI tool, ProPicks AI, evaluates NAMS among other companies using financial metrics.

Davidson Michael H. (Chief Executive Officer) purchased 10,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at $22.65 ($0.23M total) on 2026-09-14.

Novartis (NVS) and Ionis (IONS) reported that their drug pelacarsen failed to reduce cardiovascular risks, despite lowering Lp(a) levels. This led to declines in NewAmsterdam Pharma (NAMS), Amgen (AMGN), and Eli Lilly (LLY) stocks. The news impacted biotech stocks on Tuesday.